IAS 2025: HIV funding crisis the focus of IAS 2025, 16 July 2025
HIV funding crisis the focus of IAS 2025
Related Articles
IAS 2025: Monthly oral PrEP pill advances to phase III trials, 18 July 2025
Monthly oral PrEP pill advances to phase III trials
Injectable HIV treatment works for people with poor HIV control in Africa
Injectable treatment with long-acting cabotegravir and rilpivirine is as effective as dolutegravir-based oral treatment in adults with HIV in sub-Saharan Africa who have a history…
Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding
New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and…
Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns
Intermittent HIV treatment schedules – such as weekends off treatment – may not be inferior to continuous treatment in adults with well-controlled HIV, but they…
Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year
The 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda has been dominated by the impact of the US government funding cuts.…
Treatment changes do not reduce weight in people with HIV
A randomised trial presented on Tuesday at the 13th International AIDS Society Conference on HIV Science (IAS 2025) showed that switching from medications thought to cause weight…
Language matters
At the IAS, we actively use language that puts people first. This is because words have power: they bestow or remove dignity, build or break…
One Visit, One Test, Three Results: The Triple Elimination Test Steps Up Global MTCT Fight
A groundbreaking diagnostic tool recently prequalified by the World Health Organization (WHO) is set to revolutionize efforts to eliminate mother-to-child transmission (MTCT) of three major…
Once-monthly oral PrEP moves into late-stage trials
An investigational once-monthly pill holds promise for HIV pre-exposure prophylaxis (PrEP), according to mid-stage study results presented yesterday at the 13th International AIDS Society Conference…